Emergent BioSolutions has purchased PaxVax for $270 million. PaxVax produces two specialty vaccines: Vivotif, the only oral vaccine approved for prevention of typhoid fever, and Vaxchora, the only FDA-approved vaccine for preventing cholera.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.